Secondary endpoints
neurotoxicity, death
ADVERSE EVENTS

The proportion of patients in the ctDNA guided arm receiving SOC ACTThe proportion of patients in the ctDNA guided arm who are ctDNA negative post-operatively who become ctDNA positive during follow up and receive chemotherapy as an escalation of treatmentThe difference in overall survival (OS) between the two arms, measured from the time of randomisation to death from any causeThe difference in neurotoxicity between the two arms, with data based on FACT/GOG-Ntx4 and common terminology criteria of adverse events (CTCAE) version 5The difference in quality of life between the two arms, with data based on EORTC QLQ-C30 and CR29 and EQ-5D-3LThe cost-effectiveness of ctDNA guided arm compared to the SOC arm, with data based on a dedicated health economic questionnaire (RUtINE.™)